Prolactin in Autoimmune Disease

Principles of Gender-Specific Medicine

Volumn 2, Issue , 2004, Pages 1128-1138

  Walker, Sara E ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902063444     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012440905-7/50379-0     Document Type: Chapter

References (152)

1. Neill JD, Nagy GM Prolactin and its secretion. The physiology of reproduction 1994, 1833-2860. Raven Press, New York. E. Knobil, J.D. Neill (Eds.).
2. Montgomery DW Prolactin production by immune cells. Lupus 2001, 10:665-675.
3. Weigent DA Immunoregulatory properties of growth hormone and prolactin. Pharmacol Ther 1996, 69:237-257.
4. Yu-Lee LY Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002, 57:35-55.
5. Dogusan Z, Hooghe R, Verdood P, et al. Cytokine-like effects of prolactin in human mononuclear and polymorphonuclear leukocytes. J Neuroimmunol 2001, 120:58-66.
6. Matera L, Mori M, Galetto A Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus 2001, 10:728-734.
7. Special Issue. prolactin in SLE. Lupus 1998, 7:371-420.
8. Walker SE, Yu-Lee LY Special Issue. Prolactin and systemic lupus erythematosus: Mechanisms and clinical studies. Lupus 2001, 10:659-762.
9. Neuroimmune Biology. Vol. 2. Growth and Lactogenic Hormones 2002, Elsevier, Amsterdam. L. Matera, R. Rapaport (Eds.).
10. Walker SE, McMurray RW, Houri JM, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Proc NY Acad Sci 1998, 840:762-772.
11. Walker SE, Jacobson JD Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. Rheum Dis Clin North Am 2000, 26:713-736.
12. Thoreau E, Petridou B, Kelly PA, et al. Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett 1991, 282:26-31.
13. Dardenne M, Savino W, Gagnerault MC, et al. Neuroendocrine control of thymic hormonal production. I. Prolactin stimulates in vivo and in vitro the production of thymulin by human and murine thymic epithelial cells. Endocrinology 1989, 125:3-12.
14. De Mello-Cuelho V, Villa-Verde DMS, Dardenne M, et al. Pituitary hormones modulate cell-cell interactions between thymocytes and thymic epithelial cells. J Neuroimmunol 1997, 76:39-49.
15. Mukherjee P, Mastro AM, Hymer WC Prolactin induction of interleukin-2 on rat splenic lymphocytes. Endocrinology 1990, 126:88-94.
16. Montogomery DW, Shen GK, Ulrich ED, et al. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. Endocrinology 1992, 131:3019-3026.
17. DiMattia GE, Gellersen B, Bohnet HG, et al. A human B-lymphoblastoid cell line produces prolactin. Endocrinology 1988, 122:2508-2517.
18. Goda K, Rimanozi E, Hasitz A, et al. Elevated levels of serum prolactin in patients with advanced multiple myeloma. Neuroimmunomodulation 2001, 9:231-236.
19. Hatfill SJ, Kirby R, Hanley M, et al. Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of sutype M4. Leuk Res 1990, 14:57-62.
20. Nagy E, Berczi I Immunodeficiency in hypophysectomized rats. Acta Endocrinol 1978, 89:530-537.
21. Berczi I, Nagy E, Kovacs K, et al. Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol 1981, 98:506-513.
22. Berczi I, Nagy E, de Toledo SM, et al. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 1990, 146:2201-2206.
23. Cross RJ, Campbell JL, Roszman TL Potentiation of antibody responsiveness after the transplatation of a syngeneic pituitary gland. J Neuroimmunol 1989, 25:29-35.
24. Bryant HU, Holaday JW, Bernton EW Cysteamine produces dose-related bidirectional immunomodulatory effects in mice. J Pharm Exp Ther 1989, 249:424-429.
25. Grimaldi CM, Michael DJ, Diamond B Cutting Edge: Expansion and activation o a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001, 167:1886-1890.
26. Peeva E, Grimaldi C, Spatz L, et al. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000, 106:1373-1379.
27. Peeva E, Michael D, Cleary J, et al. Prolactin modulates the naïve B cell repertoire. J Clin Invest 2003, 111:275-283.
28. Hahn BH Animal models of systemic lupus erythematosus. Dubois' Lupus Erythematosus 2002, 339-388. Williams & Wilkins, Baltimore. Sixth edition. D.J. Wallace, B.H. Hahn (Eds.).
29. Theofilopoulos AN, Koundouris S, Kono DH, et al. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 2001, 3:136-141.
30. Matera L, Mori M, Geuna M, et al. Prolactin in autoimmunity and antitumor defence. J Neuroimmunol 2000, 109:47-55.
31. Tada Y, Ho A, Matsuyama T, et al. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 1997, 185:231-238.
32. Walker SE, McMurray RW, Besch-Williford CL, et al. Premature death with bladder outlet obstruction and hyperprolactinemia in New Zealand Black X New Zealand White mice treated with ethinyl estradiol and 17 beta-estradiol. Arthritis Rheum 1992, 35:1387-1392.
33. Roubinian JR, Talal N, Greenspan JS, et al. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978, 147:1568-1583.
34. McMurray R, Keisler D, Kanuckel K, et al. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991, 147:3780-3787.
35. Walker SE, Allen SH, McMurray RW Prolactin and autoimmune disease. Trends Endocrinol Metabol 1993, 4:47-151.
36. McMurray RW, Keisler D, Izui S, et al. Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: Accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 1994, 71:338-343.
37. McMurray RW, Keisler D, Izui S, et al. Effects of parturition, suckling, and pseudopragnancy on variables of disease activity in the B/W mouse model of systemic lupus erythematosus. J Rheum 1993, 20:1143-1151.
38. Elbourne KB, Keisler D, McMurray RW Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus 1998, 7:420-427.
39. Rovensky J, Buc M, Jojda Z, et al. Effect of domperidone-induced hyperprolactinemia on selected immune parameters in healthy women. Arch Immunol Ther Exp. (Warsz) 1995, 43:221-227.
40. Clodi M, Svoboda T, Kotzmann H, et al. Effect of elevated serum prolactin concentrations on cytokine production and natural killer cell activity. Neuroendocrinology 1992, 56:775-779.
41. Koller M, Kotzmann H, Clodi M, et al. Effect of elevated serum prolactin concentrations on the immunophenotype of human lymphocytes, mitogen-induced proliferation and phagocylic activity of polymorphonuclear cells. Eur J Clin Invest 1997, 27:662-666.
42. Gerli R, Riccardi C, Nicoletti I, et al. Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia. J Clin Immunol 1987, 7:463-470.
43. Vidaller A, Guadarrama F, Llorente L, et al. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol 1992, 12:210-215.
44. Matera L, Ciccarelli E, Cesano A, et al. Natural killer activity in hyperprolactinemic patients. Immunopharmacology 1989, 18:143-146.
45. Pontiroli AE, Falsetti L, Bottazzo G Clinical, endocrine, roentgenographic, and immune characterization of hyperprolactinemic women. Int J Fertil 1987, 32:81-85.
46. Ishibashi M, Kuzuya N, Sawada S, et al. Anti-thyroid antibodies in patients with hyperprolactinemia. Endocrinol Jpn 1991, 38:517-522.
47. Buskila D, Berezin M, Gur H, et al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun 1995, 8:415-424.
48. Toubi E, Gabriel D, Golan TD High association between hyperprolactinemia and anticardiolipin antibodies. J Rheumatol 1997, 24:1451. (letter).
49. Kawai T, Katoh K, Tani K Hyperprolactinemia preceding development of autoimmune disease. J Rheumatol 1996, 23:1483-1484.
50. Haga HJ, Rygh T The prevalence of hyperprolactinemia in patients with primary Sjögren's syndrome. J Rheumatol 1999, 26:1291-1295.
51. McMurray RW, Allen SH, Braun AL, et al. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease. J Rheumatol 1994, 21:843-850.
52. Draca S, Levic Z The possible role of prolactin in the immunopathogenesis of multiple sclerosis. Med Hypotheses 1996, 47:89-92.
53. Grinsted L, Holtberg A, Hagen C, et al. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J Intern Med 1989, 226:241-244.
54. Yamasaki K, Horiuchi I, Minohara M, et al. Hyperprolactinemia in multiple sclerosis. Intern Med 2000, 39:296-299.
55. Vernant JC, Cabre P, Smadja D, et al. Recurrent optic neuromyelitis with endocrinopathies: A new syndrome. Neurology 1997, 48:58-64.
56. Heesen C, Gold SM, Bruhn M, et al. Prolactin stimulation in multiple sclerosis-an indicator of disease subtypes and activity. Endocr Res 2002, 28:9-18.
57. Azar ST, Yamout B Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res 1999, 25:207-214.
58. Lever EG, McKerron CG Auto-immune Addison's disease associated with hyperprolactinaemia. Clin Endocrinol. (Oxford) 1984, 21:451-457.
59. Legakis I, Petroyianni V, Saramantis A, et al. Elevated prolactin to cortisol ratio and polyclonal autoimmune activation in Hashimoto's thyroiditis. Horm Metab Res 2001, 33:585-589.
60. Ferrari C, Boghen M, Paracchi A, et al. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol 1983, 104:35-41.
61. Pleyer U, Gupta D, Weidle EG, et al. Elevated prolactin levels in human aqueous humor of patients with anterior uveitis. Graefes Arch Clin Exp Ophthalmol 1991, 229:447-451.
62. Hedner LP, Bynke G Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 1985, 100:618-619.
63. Palestine AG, Nussenblatt RB, Gelato M Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transpl Proc Suppl 1988, 20:131-135.
64. Jara LJ, Silveira LH, Cuellar ML, et al. Hyperprolactinemia in Reiter's syndrome. J Rheumatol 1994, 21:1292-1297.
65. Shahin AA, Abdoh S, Abdelrazik M Prolactin and thyroid hormones in patients with systemic sclerosis: correlations with disease manifestations and activity. Z Rheumatol 2002, 61:703-709.
66. Kucharz EJ, Jarczyk R, Jonderko G, et al. High serum levels of prolactin in patients with systemic sclerosis. Clin Rheumatol 1996, 15:314.
67. Steinfeld S, Rommes S, Francois C, et al. Big prolactin 60 kDa is overexpressed in salivary glandular epithelial cells from patients with Sjögren's syndrome. Lab Invest 2000, 80:239-247.
68. Gutierrez MA, Anaya JM, Scopelitis E, et al. Hyperprolactinaemia in primary Sjögren's syndrome. Ann Rheum Dis 1994, 53:425-428.
69. Brennan P, Ollier B, Worthington J, et al. Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin?. Lancet 1996, 348:106-109.
70. Rovensky J, Bakosova J, Koska J, et al. Somatotropic, lactotropic and adrenocortical responses to insulin-induced hypoglycemia in patients with rheumatoid arthritis. Ann NY Acad Sci 2002, 966:263-270.
71. Eijsbouts A, van den Hoogen F, Laan R, et al. Similar response to adrenocorticotrophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1998, 37:1138-1139.
72. Zoli A, Ferlisi EM, Lizzio M, et al. Prolactin/cortisol ratio in rheumatoid arthritis. Ann NY Acad Sci 2002, 966:508-512.
73. Kullich WC, Klein G High levels of macrophage inflammatory protein-1 lalpha correlate with prolactin in female patients with acute rheumatoid arthritis. Clin Rheumatol 1998, 17:263-264.
74. Elhassan AM, Adem A, Suliman IA, et al. Prolactin, growth hormone, and IGF-1 in ankles and plasma of adjuvant arthritis rats. Scand J Rheumatol 1999, 28:368-373.
75. Nagafuchi H, Suzuki N, Kaneko A, et al. Prolactin locally produced by synovium infitrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999, 26:1890-1900.
76. Seriolo B, Ferretti V, Sulli A, et al. Serum prolactin concentrations in male patients with rheumatoid arthritis. Ann N Y Acad Sci 2002, 966:258-262.
77. Lieberman S, Gurfinkiel M, Damilano S, et al. Prolactin and IgG prolactin complex levels in patients with rheumatic arthritis. An N Y Acad Sci 2002, 966:252-257.
78. Mateo L, Nolla JM, Bonnin MR, et al. High serum prolactin levels in men with rheumatoid arthritis. J Rheumatol 1998, 25:2077-2082.
79. Templ E, Koeller M, Riedl M, et al. Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Br J Rheumatol 1996, 35:350-356.
80. Guiterrez MA, Garcia ME, Rodriguez JA, et al. Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: A controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 1999, 26:277-281.
81. Nagy E, Chalmers IM, Barager FD, et al. Prolactin deficiency in rheumatoid arthritis. J Rheumatol 1991, 18:1662-1668.
82. Cutolo M, Balleari E, Giusti M, et al. Sex hormone status in women suffering from rheumatoid arthritis. J Rheumatol. 1986, 13:1019-1023.
83. Jiminez-Balderas FJ, Tapia-Serrano R, Madero-Cervera JI, et al. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J Rheumatol. 1990, 17:497-502.
84. Gordon D, Beastall GH, Thomson JA, et al. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. Quart J Med. 1986, 60:671-679.
85. Tapia-Serrano R, Jimenez-Balderas FJ, Murrieta S, et al. Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin. J Rheumatol. 1991, 18:841-848.
86. Buskila D, Fefer P, Harman-Boehm I, et al. Assessment of nonarticular tenderness and prevalence of fibromyalgia in hyperprolactinemic women. J Rheumatol. 1993, 20:2112-2115.
87. Adler GK, Kinsley BT, Hurwitz S, et al. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999, 106:534-543.
88. Keser G, Oksel F, Ozgen G, et al. Serum prolactin levels in Behçet's syndrome. Clin Rheumatol. 1999, 18:351-352.
89. Apaydin KC, Duranoglu Y, Ozgurel Y, et al. Serum prolactin levels in Behçet's disease. Jpn J Ophthalmol 2000, 44:442-445.
90. McMurray RW, Allen SH, Pepmueller PH, et al. Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. J Rheumatol 1995, 22:1577-1580.
91. Picco P, Gattorno M, Buoncompagni A, et al. Prolactin and interleukin 6 in prepubertal girls with juvenile chronic arthritis. J Rheumatol. 1998, 25:347-351.
92. Allen SH, Sharp GC, Wang G, et al. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease. Lupus 1996, 5:30-37.
93. Lavalle C, Loto E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987, 14:268-272.
94. Jara-Quezada L, Graef A, Lavalle C Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1991, 18:349-353.
95. Jara LJ, Gomez-Sanchez C, Silveira LH, et al. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci. 1992, 303:222-226.
96. Pauzner R, Urowitz MB, Gladman DD, et al. Prolactin in systemic lupus erythematosus. J Rheumatol 1994, 21:2064-2067.
97. Neidhart M Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1996, 23:476-481.
98. Buskila D, Lorber M, Neumann L, et al. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 1996, 23:629-632.
99. Huang CM, Chou CT Hyperprolactinemia in systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi (Taipei) 1997, 59:37-41.
100. Rovensky J, Jurankova E, Rauova L, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J Rheumatol 1997, 24:2330-2334.
101. Jimena P, Aguirre MA, Lopez-Curbelo A, et al. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus 1998, 7:383-386.
102. Pacilio M, Migliaresi S, Meli R, et al. Elevated bioactive prolactin levels in systemic lupus erythematosus-Association with disease activity. J Rheumatol 2001, 28:2216-2221.
103. Jacobi AM, Rohde W, Ventz M, et al. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001, 10:554-561.
104. Ostendorf B, Fischer R, Santen R, et al. Hyperprolactinemia in systemic lupus erythematosus. Scand J Rheumatol 1996, 25:97-102.
105. Munoz JA, Gil A, Lopez-Dupla JM, et al. Sex hormones in chronic systemic lupus erythematosus. Correlation with clinical and biological parameters. Ann Med Interne (Paris) 1994, 145:459-463.
106. Zoli A, Ferlisi EM, Pompa A, et al. Basal and after-stimuli test for prolactinemia in systemic lupus erythematosus. Ann N Y Acad Sci 1999, 876:155-158.
107. Leanos-Miranda A, Pascor-Lira D, Chavez-Rueda KA, et al. Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol 2001, 28:1546-1553.
108. Miranda JM, Prieto RE, Paniagua R, et al. Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus 1998, 7:387-391.
109. Athreya BH, Rafferty JH, Sehgal GS, et al. Adenohypophyseal and sex hormones in pediatric rheumatic disease. J Rheumatol 1993, 20:725-730.
110. El-Garf A, Salah S, Shaarawy M, et al. Prolactin hormone in juvenile systemic lupus erythematosus: A possible relationship to disease activity and CNS manifestations. J Rheumatol 1996, 23:374-377.
111. Gutierrez MA, Molina JF, Jara LJ, et al. Prolactin and systemic lupus erythematosus: Prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Lupus 1995, 4:348-352.
112. Jara LJ, Alcala M, Vera-Lastra O, et al. Hyperprolactinemia secondary to microadenoma and systemic lupus erythematosus: An analysis of 36 cases. Accepted for presentation, 2003 Scientific Session 2003.
113. Ferreira C, Paes M, Gouveia A, et al. Plasma homovanillic acid and prolactin in systemic lupus erythematosus. Lupus 1998, 7:392-397.
114. Leanos A, Pascoe D, Fraga A, et al. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 1998, 7:398-403.
115. Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA, et al. Persistence of macroprolactinemia due to antiprolactin autoantibody before, during, and after pregnancy in a woman with systemic lupus erythematosus. Clin Endocrinol Metab. 2001, 86:2619-2624.
116. Parkes D Bromocriptine. N Engl J Med. 1979, 301:873-878.
117. Vance ML, Evans WS, Thorner MO Bromocriptine. Diagnosis and treatment. Drugs five years later. Ann Intern Med. 1984, 100:78-91.
118. McMurray RW Bromocriptine in rheumatic and autoimmune diseases. Semin. Arthritis Rheum 2001, 31:21-32.
119. Walker SE Effectiveness of bromocriptine in the treatment of autoimmune diseases. Neuroimmune Biology. Vol. 2: Growth and Lactogenic Hormones 2002, 287-296. Elsevier, Amsterdam. L. Matera, R. Rapaport (Eds.).
120. Hiestand PC, Mekler P, Nordmann R, et al. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci U S A 1986, 83:2599-2603.
121. Nagy E, Berczi I, Wren GE, et al. Immunomodulation by bromocriptine. Immunopharmacology 1983, 6:231-243.
122. Bernton EW, Meltzer MS, Holaday JW Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 1988, 239:401-404.
123. Morikawa K, Oseko F, Morikawa S Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. Clin Exp Immunol 1993, 93:200-205.
124. Morikawa K, Oseko F, Morikawa S Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 1994, 95:514-518.
125. Neidhart M Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. Biomed Pharmacother 1997, 51:118-125.
126. Palestine AG, Muellenberg-Coulombre CG, Kim MK, et al. Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest 1987, 79:1078-1081.
127. Neidhart M Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats. Experientia 1996, 52:892-899.
128. Riskind PN, Massacesi L, Doolittle TH, et al. The role of prolactin in autoimmune demyelination: Suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol. 1991, 29:542-547.
129. Berczi B, Nagy E, Asa SL, et al. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum 1984, 27:682-688.
130. Neidhart M Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund's complete adjuvant in lymphoid tissues of male rats. Endocrinology 1989, 125:2846-2852.
131. Dijkstra CD, Rouppe van der Voort E, De Groot CJA, et al. The therapeutic effect of bromocriptine on acute and chronic experimental allergic encephalomyelitis. Ann Neurol. 1992, 31:450-451.
132. Dijkstra CD, Rouppe van der Voort E, De Groot CJA, et al. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology 1994, 19:135-142.
133. Mahon JL, Gunn HC, Stobie K, et al. The effect of bromocriptine and cyclosporine on spontaneous diabetes in BB rats. Transplant Proc. 1998, 20(Suppl):197-200.
134. Hawkins TA, Gala RR, Dunbar JC Prolactin modulates the incidence of diabetes in male and female NOD mice. Autoimmunity 1994, 18:155-162.
135. Durant S, Alves V, Coulaud J, et al. Attempts to pharmacologically modulate prolactin levels and type 1 autoimmune diabetes in the non-obese diabetic (NOD) mouse. J Autoimmun. 1995, 8:875-885.
136. Blank M, Krause I, Busila D, et al. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol. 1995, 162:114-122.
137. Hedner LP, Bynke G Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 1985, 100:618-619.
138. Palestine AG, Nussenblatt RB, Gelato M Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transpl Proc. 1988, 20:131-135.
139. Schaaf L, Zierhut M, Baur EM, et al. Bromocriptine in patients with chronic autoimmune-associated disorders. Klin Wochenschr. 1991, 69:943.
140. Bravo G, Zazueta B, Lavalle C An acute remission of Reiter's syndrome in male patients treated with bromocriptine. J Rheumatol. 1992, 19:747-750.
141. Figueroa FE, Carrion F, Martinez ME, et al. Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 1997, 36:1022-1023.
142. Eijsbouts A, van den Hoogen F, Laan R, et al. Treatment of rheumatoid arthritis with the dopamine agonist quinagolide. J Rheumatol 1999, 26:2284-2285.
143. Ingvarsson CG Prolactin in rheumatoid arthritis (A therapeutic test). Acta Rheum Scand 1969, 15:4-17.
144. Bissay V, De Klippel N, Herroelen L, et al. Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol. 1994, 17:473-476.
145. Wasada T, Kawahara R, Iwamoto Y Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000, 23:1040.
146. Atkison PR, Mahon JL, Dupre J, et al. Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study. J Autoimmun 1990, 3:793-797.
147. Rabiniovich CE, Schanberg LE, Kredich DW Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1990, 33(Suppl.):R22. (Abstract).
148. Funauchi M, Ikoma S, Enomoto H, et al. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol. 1998, 16:479-482.
149. McMurray RW, Weidensaul D, Allen SH, et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995, 22:2084-2091.
150. Walker SE, Smarr KL, Parker JC, et al. Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine. Lupus 2000, 9:527-533.
151. Alvarez-Nemeguei J, Cobarrubias-Cobbs A, Escalante-Triay F, et al. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study. Lupus 1998, 7:414-419.
152. Walker SE, Reddy GH, Miller D, et al. Treatment of active systemic lupus erythematosus (SLE) with the prolactin (PRL) lowering drug, bromocriptine (BC): Comparison with hydroxychloroquine (HC) in a randomized, blinded one-year study. Arthritis Rheum 1999, 42.